Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.40 |
| ▸ | HTR6 | P50406 | 5/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.33 |
| ▸ | HTR1A | P08908 | 3/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11437886 | 0.68 | SLC18A3 (0.52) | HTR2CSLC6A2SLC6A4SLC6A3SLC18A3 | |
| Hydrochloric Acid SCHEMBL4676075 | 0.67 | HTR2C (0.57) | HTR2CHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4245090 | 0.67 | CCR5 (0.34) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30493303 | 0.63 | HTR2C (0.72) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL23228720 | 0.63 | HTR2C (0.45) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| Hydrochloric Acid SCHEMBL23209867 | 0.62 | HTR2C (0.46) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL19139827 | 0.62 | HTR2C (0.59) | HTR2CHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27565324 | 0.59 | HTR2C (0.51) | HTR2CHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1513258 | 0.59 | HTR2C (1.00) | HTR2CHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9925465 | 0.59 | HTR2C (0.60) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491735-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1708703-A4 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC (CA) | 2008-04-09 | — | — | EP | disclosed |
| EP-1708703-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-10-11 | — | — | EP | disclosed |
| US-20050277670-A1 | Chemokine receptor binding compounds | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005059107-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277670-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | HTR2C 2293/4885HTR6 2051/4885SLC6A2 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.